Invivyd's Participation in Future Investor Conferences
Invivyd, Inc. (Nasdaq: IVVD) has exciting news for its investors! The company is set to showcase its advancements and insights at notable upcoming investor conferences, with a strong focus on innovation in the biopharmaceutical field.
Cantor Global Healthcare Conference 2025
One of the highlighted events is the Cantor Global Healthcare Conference, where Invivyd will participate in a fireside chat. This event is scheduled for a mid-afternoon slot, aiming to maximize engagement with potential and current investors.
Event Details
The fireside chat is set to take place on a Wednesday in early September, providing an opportunity for Invivyd's management to discuss their strategic initiatives and clinical advancements.
H.C. Wainwright 27th Annual Global Investment Conference
Following the Cantor Conference, Invivyd will also take part in the H.C. Wainwright 27th Annual Global Investment Conference. This annual event is known for attracting a diverse group of investors and industry leaders.
Interactive Engagement
Scheduled for later in the same week, the company will again engage in a fireside chat, further elaborating on its mission to combat serious viral infectious diseases.
Opportunity for Individual Meetings
Beyond the formal presentations, Invivyd's management team is eager to connect with investors in one-on-one meetings. This not only allows for more personalized interaction but also provides an avenue for deeper insights into the company’s pipeline and future prospects.
About Invivyd and Its Mission
Invivyd, Inc. is dedicated to protecting individuals from serious viral infections. The biopharmaceutical company focuses primarily on SARS-CoV-2, utilizing a proprietary technology platform uniquely positioned within the industry to assess, monitor, develop, and adapt antibody therapies.
Innovative Developments
Recently, Invivyd achieved a significant milestone by obtaining emergency use authorization from the U.S. FDA for one of its monoclonal antibody candidates. This approval reflects the company's commitment to delivering effective treatment solutions and demonstrates its role as a leader in the biopharmaceutical landscape.
Get Involved!
Investors interested in participating in the fireside chats are encouraged to reach out to their respective representatives from Cantor or H.C. Wainwright. This is a fantastic opportunity to gain insights directly from the management team of Invivyd.
Contacts at Invivyd
For media inquiries, you can reach out to Invivyd's Media Relations team at (781) 208-1747 or via email at media@invivyd.com. Investors can also contact the Investor Relations team at the same phone number or at investors@invivyd.com for further information or to schedule meetings.
Frequently Asked Questions
What is the focus of Invivyd?
Invivyd focuses on delivering protection against serious viral infectious diseases, particularly aiming at SARS-CoV-2.
When and where will the investor conferences be held?
The Cantor Global Healthcare Conference is on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference is on September 8, 2025, both held in New York.
How can investors meet with Invivyd's management?
Interested investors should contact their representatives from Cantor or H.C. Wainwright to arrange individual meetings with Invivyd's management team.
What kind of innovations does Invivyd pursue?
Invivyd utilizes a proprietary integrated tech platform to create and adapt antibody therapies, aiming to lead in viral infectious disease treatments.
How can I get the latest updates from Invivyd?
Investors can tune into the company's website for live webcasts of events and updates on their product developments and conferences.
